Snehal Gis: Gene Therapy Revolutionizing the Hemophilia Treatment Landscape
Snehal Gis, Senior Digital Analyst Manager and Senior Research Associate at Global Insight Services shared a post on LinkedIn:
”The Hemophilia Gene Therapy Market is entering a transformative phase, driven by the promise of long-term or potentially curative treatments for patients suffering from hemophilia, a rare genetic bleeding disorder.
Unlike traditional therapies that rely on frequent factor replacement infusions, gene therapy introduces functional copies of defective genes into a patient’s cells, enabling the body to produce clotting factors naturally.
This shift represents a paradigm change in treatment approaches, offering improved quality of life and reduced lifetime healthcare costs.
Click to Request a Sample of this Report for Additional Market Insights.”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments